Voluntary nationwide recall: Brexafemme

Oct. 2023Pharmacy Updates
Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.

Recent Announcements

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Oct. 2026Education/Webinars

CME Webinar: Navigating Grief Conversations

Please join us for a live, CME-accredited webinar on Thursday, Nov. 12, 2026, that will enhance your confidence and effectiveness in supporting patients dealing with loss & grief.
Oct. 2026Education/Webinars

Provider OnLine Login Changes for UPMC Employees and UPMC Children’s Hospital of Pittsburgh Employees

UPMC employees and UPMC Children’s Hospital of Pittsburgh employees will now use their email address to access Provider OnLine.
Oct. 2026Important Notices